Member Info for arsenal58

There is no stamp Mary with this stock

Been trading it for a few years very predictable what happened yesterday

The big boys are all loaded 🤑 on Beazly

they sent it to the moon with huge orders attracted the masses and sold into the buying

Overdone his not the word

How about this ??

If you are in profit like me !! Tender the amount of shares to release your profit !!

Hold on to the rest of you think there’s bigger riches around the corner

Just like top slicing any other share

You could even tender your outlay amount of shares and have a free ride !!

Depends how much faith in PRTC you have ??

Whatever you choose GLA

Sorry

20 th of June is the cut off

No dates have been set

So load up chap

can you believe this bunch of crooks running the markets ??

$29.70 finish in the states £2.14 open here

daylight robbery

they are doing the same ****e with rio tinto

unbelievable liberty’s being taken

gla we all need it on this market

That

Mobil will pull the sale of assets now there’s a sensible government in power 😝

Even in Nigerian time this is wrong

Thoughts

Still holding though !!

These US sites can make you look like a right dipstick

27.54 now apparently

It finished last night on the Nasdaq @$30.91 divided by 10 =3.091 divided by 1.26=£2.45

The septics are not waiting to miss the bargain basement offer

You will be able to tender has many as you have

If it’s oversubscribed you will not get your full amount

It won’t be at this price lol 😂

Dallo

I am also a longtime bull of this share has you know

But luckily for me I have traded it for a number of years now

With this pittance being offered to shareholders and the tender offer to lower the shareholding as well has the buyback

I smell an agenda from management to either sell the company or a management buyout for has cheap as possible??

This will also explain why the septics in the know are not kicking the doors down to buy it on the Nasdaq !!

I raised my holdings yesterday to my maximum hold and I am averaging 198.5 a share leaves me in a comfortable position whatever occurs ??

This outfit Dallo has been promising holders payouts for a good couple of years now not once have they kept their word !!

I hope you long term sit and hold gang get something in return!!

But I am afraid to say I am happier in my boat than yours!!

GLA.

Lesley !!

Try looking 👀 on the bright side of life old chap

Either average down or sit tight and hope for a return on your 4 pound outlay

Not sure share trading is your forte !!?

So I will double my holding too twelve thousand shares buying six thousand at 2.20ish

I will then take the tender offer for six thousand which will leave me with six thousand to carry on

Anyone who are in at much higher prices it’s time to buy buy buy to lower your averages surely??

1. The proposal to adopt the Merger Agreement, pursuant to which, subject to the terms and conditions set forth therein, Merger Sub will be merged with and into Karuna, the separate corporate existence of Merger Sub will cease, and Karuna will survive the merger as a wholly owned subsidiary of Parent (the “merger”):

Votes For

Votes Against

Abstentions

Broker Non-Votes

30,954,183

1,430

1,336

0

2. The proposal to approve, on a non-binding, advisory basis, certain compensation that will or may be paid by Karuna to its named executive officers that is based on or otherwise relates to the merger:

Votes For

Votes Against

Abstentions

Broker Non-Votes

25,312,364

5,523,004

121,581

0

3. In connection with the Karuna Special Meeting, the board of directors of Karuna also solicited proxies with respect to the proposal to adjourn the Karuna Special Meeting from time to time, if necessary or appropriate, as determined in good faith by the board of directors of Karuna, including for the purpose of soliciting additional votes for the approval of the proposal to adopt the Merger Agreement if there are insufficient votes at the time of the Karuna Special Meeting to approve the proposal to adopt the Merger Agreement (the “adjournment proposal”). The adjournment proposal was not submitted to Karuna stockholders for approval at the Karuna Special Meeting because a quorum of stockholders entitled to vote at the Karuna Special Meeting was present or represented by proxy and the Karuna stockholders approved the proposal to adopt the Merger Agreement.

Assuming timely satisfaction of necessary closing conditions, the parties to the Merger Agreement expect the merger to close during the first half of 2024.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 12, 2024

Karuna Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-38958

27-0605902

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

99 High Street, Floor 26

Boston, Massachusetts

02110

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 857 449-2244

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common stock, par value $0.0001

KRTX

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07

Submission of Matters to a Vote of Security Holders.

On March 12, 2024, Karuna Therapeutics, Inc., a Delaware corporation (“Karuna”) held a special meeting of stockholders (the “Karuna Special Meeting”) at which holders of Karuna’s common stock, par value $0.0001 per share, approved each of the proposals voted on at the Karuna Special Meeting relating to the transactions contemplated by the Agreement and Plan of Merger, dated as of December 22, 2023 (as it may be amended from time to time, the “Merger Agreement”), by and among Karuna, Bristol-Myers Squibb Company, a Delaware corporation (“Parent”), and Miramar Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”). Of the 38,119,463 shares of Karuna’s common stock issued and outstanding at the close of business on January 26, 2024, the record da

Old

I have checked the Bristol meyers Squibb site

Nor a mention that the deal went through???

Can anyone find a definite acceptance that the Karuna deal has gone through ??

MARKETS

PRTC

+0.19%

RTTNews-Logo

PureTech Health Gets FDA's Orphan Drug Designation For LYT-200 In Acute Myeloid Leukemia

March 13, 2024 — 07:55 am EDT

Written by RTTNews.com for RTTNews ->

I am wondering if the top brass at hsbc are telling us some porkys about the Chinese economy

https://www.youtube.com/live/J4_mTqUXexc?feature=shared

Karuna CEO, Board Sued by Shareholder over $14B BMS Acquisition

Published: Feb 16, 2024

By Tristan Manalac

Courthouse_iStock, Mariakray

Pictured: Signage above a U.S. courthouse/iStock, Mariakray

Karuna Therapeutics shareholder Shannon Jenkins this week filed a lawsuit against the company and its leadership—including CEO Bill Meury—for agreeing to and endorsing the $14 billion merger with Bristol Myers Squibb.

Jenkins is seeking to prevent the transaction and is alleging that Karuna’s directors had failed to disclose crucial material information regarding the company’s financial projections and sales processes, according to a case summary from Law.com. The plaintiff also claims that the defendants have conflicts of interests.

The lawsuit, which was filed Tuesday with the U.S. District Court for Delaware, names eight other defendants in addition to Meury: Christopher Coughlin, James Healy, Jeffrey Jonas, Laurie Olson, Atul Pande, Steven Paul, Denice Torres and David Wheadon. All sit on Karuna’s board of directors.

BMS first moved to buy Karuna in December 2023, paying $330 apiece for all of the biotech’s outstanding shares for a total deal value of approximately $14 billion. In exchange, BMS gains ownership of Karuna’s highly anticipated muscarinic antipsychotic candidate KarXT, which is being developed for schizophrenia and psychosis in Alzheimer’s disease patients.

KarXT has a target action date in September 2024 and is expected to launch in the U.S. this year, with a potential market of approximately 1.6 million patients with schizophrenia, many of whom suffer from harsh side effects of existing treatments or respond poorly.

At the time of the merger’s announcement, Karuna’s board of directors unanimously approved the merger with the companies anticipating the deal closing in the first half of 2024, pending anti-trust clearance and other customary conditions—including shareholder approval.

Earlier this month, Karuna filed a proxy statement to the SEC inviting stockholders to an online special meeting on March 12 in order to discuss and vote on the merger with BMS. In the filing, Karuna’s board of directors unanimously recommended that shareholders vote in favor of the transaction, writing that the acquisition is “in the best interests of Karuna and its stockholders.”

In her lawsuit, Jenkins claimed that the proxy statement leaves out or misrepresents information important to the vote, including other proposed buyers, according to Fierce Biotech.

In the proxy statement, the board directors revealed that in October 2023, a “large multinational pharmaceutical company” approached Karuna with an acquisition offer at a “significant premium” to its closing price at the time. The filing does not disclose the identity of the company or the value of its initial offer.

Jenkins is looking to prevent the merger from pushing through until Karuna discloses all pertinent information to